Concord Drugs Board to Consider Q1 FY27 Un-audited Financial Results on Aug 10, 2026
RESULTS
◆ Monitor Closely
LOW RISK
📅 Filed on BSE: 03 Aug 2026, 05:21 PM IST · BSE ID: 39f366f9-14fd-43ef-beb7-02d8bad7f338
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board will meet on August 10, 2026, to review and approve its financial results for the April-June 2026 quarter.
🤖 AI Summary
- Concord Drugs Board meeting scheduled for August 10, 2026, to approve Q1 FY27 un-audited financial results.
- The Board will consider both Standalone and Consolidated financial results for the quarter ended June 30, 2026.
- The trading window for designated persons closed and will remain closed until 48 hours post results declaration.
- Meeting to be held at the Registered office, as per Regulation 29(1) of SEBI (LODR) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any action based on this announcement.
👤
Who Is Affected
All shareholders are indirectly affected as the upcoming financial results will provide updated performance metrics for the company.
🔍
Management Signal
The company's management is adhering to regulatory timelines by scheduling the board meeting to approve and declare quarterly financial results.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Board meeting on August 10, 2026 — await declaration of Q1 FY27 financial results.
Release of Un-audited Standalone financial results for Quarter ended June 30, 2026.
Release of Un-audited Consolidated financial results for Quarter ended June 30, 2026.
LOW RISK
This is a routine regulatory compliance announcement for a board meeting.
💡 Investor Takeaway
Concord Drugs Limited's Board of Directors will convene on August 10, 2026, to review and approve the Un-audited Standalone and Consolidated financial results for the quarter concluded on June 30, 2026, consistent with regulatory requirements.
📅 Company Track Record
In its previous filing on May 27, 2026, Concord Drugs reported FY26 net sales up 73.92% to Rs. 7,873.68 lakhs and profit up 213.82% to Rs. 105.50 lakhs for the period ended March 31, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
When is the Board Meeting of Concord Drugs Limited scheduled?
The Board Meeting of Concord Drugs Limited is scheduled to be held on Monday, August 10, 2026.
What is the primary agenda of the upcoming Board Meeting for Concord Drugs?
The primary agenda is to consider and approve the Un-audited Standalone and Consolidated financial results for the quarter ended June 30, 2026.
When did the trading window close for Concord Drugs Limited?
The trading window for dealing in Concord Drugs Limited's equity shares closed for all designated persons and their immediate relatives effective August 03, 2026.
When will the trading window reopen for Concord Drugs Limited?
The trading window will remain closed till 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.